5 research outputs found
Additional file 2: of Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom
Survey instrument: time trade-off exercise. (DOCX 58 kb
Additional file 1: of Management and treatment of relapsed or refractory Ph(âÂÂ) B-precursor ALL: a web-based, double-blind survey of EU clinicians
Abbreviated version of questionnaire. (DOCX 33 kb
Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
<p><strong>Article full
text</strong></p>
<p><br>
The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-016-0447-x"><b>here</b>.</a><br>
<br>
<strong>Provide enhanced digital features for this article</strong><br>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>[email protected]</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are
not limited to:<br>
⢠Slide decks<br>
⢠Videos and animations<br>
⢠Audio abstracts<br>
⢠Audio slides<u></u></p
Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review
<p><b>Objective:</b> Philadelphia chromosome negative [Ph(â)] relapsed or refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) is an extremely rare condition requiring intensive treatment. This retrospective chart review aimed to quantify hospitalizations and reimbursement in this patient population in France.</p> <p><b>Methods:</b> Patients aged âĽ18 years and with at least one hospitalization for Ph(â) R/R B-precursor ALL were included in the study. They were relapsed with first remission lasting <12 months, relapsed after first salvage therapy, relapsed any time after hematopoietic stem cell transplant (HSCT), or were refractory to initial or salvage therapy. Data were collected from the index date (first diagnosis of R/R ALL) until death or loss to follow-up. The chemotherapy period was defined as the first chemotherapy date after the index date to the earliest of death, loss to follow-up, last chemotherapy dose plus 30 days, or initiation of HSCT. The primary outcome was the percentage of time hospitalized during the chemotherapy period.</p> <p><b>Results:</b> Thirty-three patients were included, with a mean age of 49 years. The mean proportion of time spent in the hospital during the chemotherapy period was 46% (95% CI =34â57%). Patients had a mean of 2.2 (SD =1.5) inpatient hospitalizations and the mean length of stay per hospitalization was 16.8 (SD =14.8) days. During the chemotherapy period, the mean amount reimbursed per hospitalization was âŹ31 067 (SD = âŹ4850) and the total hospitalization reimbursement per patient was âŹ68 344. From the index date to death, excluding HSCT, the total reimbursement per patient was âŹ108 873.</p> <p><b>Limitations:</b> The sample size was small, although this was expected given the rarity of the patient population.</p> <p><b>Conclusions:</b> Adults with Ph(â) R/R B-precursor ALL had repeated and prolonged hospitalizations during salvage chemotherapy. Approximately half the follow-up period was spent in the hospital, and this time was associated with high economic burden in France. </p
Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the Seer-Medicare Database
<p><b>Article full text</b></p><p><br></p><p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s12325-018-0738-5">https://link.springer.com/article/10.1007/s12325-018-0738-5</a></p><p></p><p><br></p><p><b>Provide enhanced content for this
article</b></p><p><br></p><p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âÂÂmailto:[email protected]âÂÂ"><b>[email protected]</b></a>.</p><p><br></p><p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p><p><br></p><p>Other enhanced features include,
but are not limited to:</p><p><br></p><p>⢠Slide decks</p><p>⢠Videos and animations</p><p>⢠Audio abstracts</p><p>
</p><p>⢠Audio slides</p>
<p><b> </b></p